EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?

Beatrice Grabein, Francis F Arhin, George L Daikos, Luke S P Moore, V Balaji, Nathalie Baillon-Plot

Infectious Diseases and Therapy · 2024-11 · 13 (11) · 2423-2447

DOI: 10.1007/s40121-024-01044-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 01.10.2024. Verfasst von Beatrice Grabein und 5 weiteren Autor:innen. Beteiligte Einrichtung: LMU Hospital Munich, Munich, Germany. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The spread of carbapenemase-producing gram-negative pathogens, especially those producing metallo-β-lactamases (MBLs), has become a major health concern. MBLs are molecularly the most diverse carbapenemases, produced by a wide spectrum of gram-negative organisms, including the Enterobacterales, Pseudomonas spp., Acinetobacter baumannii, and Stenotrophomonas maltophilia, and can hydrolyze most β-lactams using metal ion cofactors in their active sites. Over the years, the prevalence of MBL-carrying isolates has increased globally, particularly in Asia. MBL infections are associated with adverse clinical outcomes including longer length of hospital stay, ICU admission, and increased mortality across the globe. The optimal treatment for MBL infections not only depends on the pathogen but also on the underlying resistance mechanisms. Currently, there are only few drugs or drug combinations that can efficiently offset MBL-mediated resistance, which makes the treatment of MBL infections challenging. The rising concern of MBLs along with the limited treatment options has led to the need and development of drugs that are specifically targeted towards MBLs. This review discusses the prevalence of MBLs, their clinical impact, and the current treatment options for MBL infections and their limitations. Furthermore, this review will discuss agents currently in the pipeline for treatment of MBL infections.

Schlagwörter

Stichwörter der Autor:innen

AvibactamAztreonamCarbapenem resistantCefiderocolMetallo-β-lactamase

Autor:innen und Institutionen

  • LMU Hospital Munich, Munich, Germany.
  • Pfizer, Kirkland, Canada.
  • National and Kapodistrian University of Athens, Athens, Greece.
  • Chelsea & Westminster NHS Foundation Trust, London, UK.
  • Imperial College London, NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK.
  • Department of Clinical Microbiology, Christian Medical College, Vellore, India.

Förderung

  • Pfizer

Zitieren

APA

Grabein, B., Arhin, F. F., Daikos, G. L., Moore, L. S. P., Balaji, V., & Baillon-Plot, N. (2024). Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?. Infectious Diseases and Therapy, 13(11), 2423-2447. https://doi.org/10.1007/s40121-024-01044-8

Vancouver

Grabein B, Arhin FF, Daikos GL, Moore LSP, Balaji V, Baillon-Plot N. Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?. Infectious Diseases and Therapy. 2024;13(11):2423-2447. doi:10.1007/s40121-024-01044-8

BibTeX
@article{Grabein2024,
  author = {Grabein, Beatrice and Arhin, Francis F and Daikos, George L and Moore, Luke S P and Balaji, V and Baillon-Plot, Nathalie},
  title = {Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?},
  journal = {Infectious Diseases and Therapy},
  year = {2024},
  volume = {13},
  number = {11},
  pages = {2423--2447},
  doi = {10.1007/s40121-024-01044-8}
}
Kostenlos starten →